Drugs Made In America Acquisition Stock (NASDAQ:DMAA)

Ownership Financials Chart

Previous Close

$10.80

52W Range

$10.23 - $10.80

50D Avg

$10.71

200D Avg

$10.54

Market Cap

$262.19M

Avg Vol (3M)

$33.45K

Beta

0.00

Div Yield

-

DMAA Company Profile

Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.

Industry

Shell Companies

Sector

Financial Services

Exchange

NASDAQ

ADR

-

Country

US

Employees

2

IPO Date

Jan 27, 2025

Website

DMAA Performance

DMAA Financial Summary

	Dec 25	Dec 24
Revenue	-	-
Operating Income	-	$-479.00
Net Income	$3.97M	$-479.00
EBITDA	-	-
Basic EPS	$0.19	$-0.06
Diluted EPS	$0.19	$-0.06

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
MLAC	Mountain Lake Acquisition Corp.
LOKV	Live Oak Acquisition Corp. V Class A Ordinary Shares
OYSE	Oyster Enterprises II Acquisition Corp
ALF	Centurion Acquisition Corp.
RTAC	Renatus Tactical Acquisition Corp I Class A Ordinary Shares
SIMA	SIM Acquisition Corp. I
TACH	Titan Acquisition Corp.
TACO	Berto Acquisition Corp.